Endoscopic, histologic improvements in EoE sustained at 52 weeks with etrasimod

WASHINGTON — Once-daily etrasimod 1 mg and 2 mg was well-tolerated and sustained improvements in histological and endoscopic features of eosinophilic esophagitis, as well as patient symptoms, through 52 weeks of treatment, according to data.
“Etrasimod is a an oral, once-daily selective sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active

Related Keywords

Washington , United States , Bykate Burba , Evans Dellon , Heather Biele , University Of North Carolina School Medicine , Esophageal Diseases , North Carolina School , Digestive Disease , Digestive Disease Week , Eoe Histology Scoring System , Eoe Endoscopic Reference Score , Patient Global Impression , Dysphagia Symptom Questionnaire ,